Strengthening Collaboration for Effective HIV Management

𝐍𝐚𝐢𝐫𝐨𝐛𝐢, 𝐊𝐞𝐧𝐲𝐚 - 7th August 2024 - In a significant move to bolster HIV management and prevention efforts, Dr. Rose Wafula, Head of NASCOP, and Dr. Waqo Erjesa, CEO of KEMSA, met today with their respective HIV Commodity and technical teams. The primary focus of the meeting was to discuss the status and management of HIV commodities in Kenya. 

The collaboration between NASCOP and KEMSA has played a pivotal role in advancing the country's efforts in HIV management and prevention. Currently, over 1.3 million people in Kenya are on antiretroviral (ARV) therapy to maintain viral suppression. These individuals also benefit from various prevention services and commodities, including Post Exposure Prophylaxis (PEP), Pre-Exposure Prophylaxis (PrEP), condoms, needle and syringe exchange programs, and opioid substitution therapy. During the meeting, it was confirmed that there is a steady supply of these essential commodities. 

To further ensure the continuity of services, KEMSA has operationalized a 72-hour Rapid Result Initiative (RRI). This initiative will be active across all counties over the next 72 hours to ensure uninterrupted access and distribution of essential HIV commodities. 

The Ministry of Health continues to emphasize the importance of maintaining a steady supply of HIV prevention and treatment commodities as a crucial component of the country's HIV response strategy. 

The collaborative efforts between NASCOP and KEMSA underscore the commitment to achieving sustained progress in HIV management and ensuring the health and well-being of all Kenyans.